AI-generated summary
This is a study protocol for a planned randomized controlled trial of morning 500 nm blue-green light therapy in adults aged 45 or older with subjective cognitive decline or amnestic mild cognitive impairment. The authors describe planned outcomes including cognition, sleep, mood and biomarkers, but no results are reported in the abstract.
- Who or what was studied
- Middle-aged and older adults aged 45 years or older with subjective cognitive decline or amnestic mild cognitive impairment, recruited from memory clinics, plus healthy controls; planned total of 150.
- Wavelengths
- 500 nm
- Limits stated in the abstract
- This is a protocol only, so no efficacy findings are reported, and the abstract describes a single-center trial with a planned 4-week duration.
Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.
Abstract
The full abstract is not shown here because it is protected by the publisher’s copyright. Read it on journals.sagepub.com.
Record from PubMed, a service of the National Library of Medicine.
Light parameters mentioned
Found in the title and abstract by pattern. They may be incomplete, so check the paper before comparing studies.
- Wavelength
- 500 nm
How to read a trial: what to check before relying on this kind of research.
Terms in this paper: Mild cognitive impairment, Cognitive decline, Randomized controlled trial, Primary outcome. Each links to its definition in the glossary.
A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.